Immune Design Corp

Entity type image
Type: Company
Name: Immune Design Corp
First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

SCYNEXIS and Immune Design Collaborate on Innovative Process for Vaccine Production Technology

TweetEmailPrint[Source]RESEARCH TRIANGLE PARK, N.C. (April 10, 2013) – SCYNEXIS, Inc. announced today that Immune Design Corp. has selected SCYNEXIS as its chemical development and cGMP production partner for manufacture of Glucopyranosyl Lipid A (GL ... [Published American Pharmaceutical Outsourcing - Apr 17 2013]
First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Immune Design, Scynexis partner for cGMP production of Glucopyranosyl Lipid A

Immune Design has partnered with Scynexis for chemical development and cGMP production of Glucopyranosyl Lipid A (GLA). ... [Published PBR - News - Apr 15 2013]

Quotes

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: "We are delighted to be working with Novartis to support a key immunotherapy programme. The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise."
Collaboration with Novartis [Published Best Invest - May 01 2013]
...Brian Ward, Professor of Medicine & Microbiology, McGill University, member of Medicago's scientific advisory committee and Medical Officer. "This H5N1 vaccine candidate represents the next generation of flu vaccines, combining our adjuvant technology with Medicago's rapid VLP technology and the intradermal delivery device from NanoPass."
Positive results for Phase I clinical trial for an H5N1 vaccine [Published Science Daily - Apr 20 2013]

More Content

All (12) | News (10) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Oxford BioMedica plc (OXB) - Financial and Stra... [Published TransWorldNews - 20 hours ago]
Oxford Biomedica PLC : Interim Management State... [Published Investegate - May 16 2013]
Collaboration with Novartis [Published Best Invest - May 01 2013]
Positive results for Phase I clinical trial for... [Published Science Daily - Apr 20 2013]
Phase I Trial Demonstrates Positive Results for... [Published MedIndia - Apr 19 2013]
Infectious Disease Research Institute (IDRI) an... [Published BioSpace - Apr 18 2013]
Medicago, IDRI's vaccine trial exceeds CHMP cri... [Published Stockwatch - Apr 17 2013]
IDRI and Medicago Report Positive Results for P... [Published FinanzNachrichten.de - Apr 17 2013]
Medicago and IDRI Reports Positive Results for ... [Published ABC News 4 Charleston - Apr 17 2013]
SCYNEXIS and Immune Design Collaborate on Innov... [Published American Pharmaceutical Outsourcing - Apr 17 2013]
Immune Design, Scynexis partner for cGMP produc... [Published PBR - News - Apr 15 2013]
SCYNEXIS and Immune Design Collaborate on Innov... [Published Marketwire - Breaking News Releases - Apr 10 2013]
1
In Focus
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Immune Design, Scynexis partner for cGMP produc... [Published PBR - News - Apr 15 2013]
Immune Design has partnered with Scynexis for chemical development and cGMP production of Glucopyranosyl Lipid A (GLA). ...
1

Press Releases

sort by: Date | Relevance
SCYNEXIS and Immune Design Collaborate on Innov... [Published Marketwire - Breaking News Releases - Apr 10 2013]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.